sapience therapeutics logosapience logo
  • About
    • Overview
    • Management
    • Directors
    • Advisors
  • Approach
    • Overview
    • Spears™
    • SPARCs™
    • Platforms
  • Pipeline
    • Overview
    • Lucicebtide (ST101)
    • ST316
    • FraAP Program
  • Clinical Trials
    • Overview
    • Lucicebtide (ST101)
    • ST316
    • Expanded Access
  • News & Events
    • Press Releases
    • Events
    • Publications
    • Presentations
    • Email Alerts
  • Careers
    • Careers
    • Open Opportunities
  • Contact

Presentations

Presentations

April 28, 2025

Reprogramming of MDSCs by ST316, a Clinical Peptide Antagonist of β-Catenin/BCL9, Enhances Anti-Tumor Immuno- and Chemotherapy

April 28, 2025

An Ex Vivo Organoid Study to Identify Biomarkers of Sensitivity to ST316, a Clinical-Stage β-Catenin Antagonist Peptide

April 28, 2025

FraAP, a Peptide Antagonist Against the Activator Protein 1 Transcription Factor Complex, Demonstrates Cancer Cell Cytotoxicity and Reduced Invasion In Vitro and Tumor Regression In Vivo in HNSCC Models

April 28, 2025

The Clinical C/EBPβ Antagonist Peptide Lucicebtide Synergizes with Molecularly Targeted Therapies in GBM

ASCO GI Conference Poster #286

January 25, 2025

Safety and Biomarker Assessment of ST316, a Novel Peptide Antagonist of β-catenin, in Patients with Advanced Solid Tumors

November 8, 2024

ST101, an Inhibitor of the Transcription Factor C/EBPβ, Promotes an Immune-Active Tumor Microenvironment in aWindow of Opportunity Study of Patients with Glioblastoma

November 8, 2024

ST316, a Peptide Antagonist of β-Catenin, Reprograms Immunosuppressive MyeloidCell Populations in a Phase 1 Clinical Study to Enhance Anti-Cancer Immune Responses

June 1, 2024

Efficacy and biomarker analysis of phase 2 and window-of-opportunity cohorts of patients with glioblastoma treated with ST101, an inhibitor of the transcription factor C/EBPβ

AACR ST316

April 9, 2024

ST316, a Clinical Peptide Antagonist of β-catenin, Induces Anti-Tumor Immune Responses by Multiple Mechanisms of Action

AACR JunAP

April 8, 2024

JunAP, a Peptide Antagonist of the Activator Protein 1 Transcription Factor, Demonstrates Cancer Cell Cytotoxicity and Reduced Invasion In Vitro and Tumor Regression In Vivo

AACR ST101

April 8, 2024

ST101, a Clinical CEBPβ Antagonist Peptide, Promotes an Immune-Active Tumor Microenvironment by Multiple Cellular Mechanisms

Neoadjuvant treatment with monotherapy ST101, a C/EBPβ antagonist, results in pathological and clinical responses in glioblastoma patients. Tissue-based analysis and clinical outcomes from a surgical window of opportunity clinical trial

November 17, 2023

Neoadjuvant treatment with monotherapy ST101, a C/EBPβ antagonist, results in pathological and clinical responses in glioblastoma patients. Tissue-based analysis and clinical outcomes from a surgical window of opportunity clinical trial

October 13, 2023

Anti-tumor and Immunostimulatory Properties of ST316, a Peptide Antagonist of β-Catenin for Treatment of Cancers with Aberrant Wnt Pathway Activity

Clinical and Biological Activity of ST101, a Peptide Antagonist of C/EBPβ, in Recurrent Glioblastoma (rGBM) Patients. Results From the rGBM Cohort of a Multi-Cohort Phase 2 Study

October 13, 2023

Clinical and Biological Activity of ST101, a Peptide Antagonist of C/EBPβ, in Recurrent Glioblastoma (rGBM) Patients. Results From the rGBM Cohort of a Multi-Cohort Phase 2 Study

Targeting the Glioblastoma Master Regulator C/EBPβ– a Pharmacokinetic and Pharmacodynamic Neoadjuvant Study of ST101

September 27, 2023

Targeting the Glioblastoma Master Regulator C/EBPβ– a Pharmacokinetic and Pharmacodynamic Neoadjuvant Study of ST101

Cover-LB236-ST101

April 24, 2023

ST101, a peptide antagonist of novel I/O target CEBPβ, reprograms MDSC polarization and promotes an immunoactive tumor microenvironment

Cover-LB016-ST316

April 24, 2023

Immunotherapeutic potential of ST316, a peptide antagonist of β-catenin

iwamoto_CTNI-49_Early signal of activity from a phase 2 study of ST101, a first-in-class peptide antagonist of CEBPbeta in recurrent glioblastoma (GBM) thumb

November 18, 2022

Early signal of activity from a phase 2 study of ST101, a first-in-class peptide antagonist of CCAAT/enhancer-binding protein β (C/EBPβ), in recurrent glioblastoma (GBM)

SITC_2022 Final (1) thumb

November 10, 2022

ST101, a peptide antagonist of novel I/O target CEBPβ, reprograms MDSC polarization and decreases tumor-associated Tregs, suggesting an immune component to observed clinical responses

Triple meeting poster (203) E_Fontana final thumb

October 27, 2022

Efficacy signals, long-term exposure and safety data from a phase 1-2 study of a cell-penetrating peptide antagonist of CEBPβ, a novel target, in patients with refractory solid tumors

Sapience ASCO poster - 2022 thumb

June 3, 2022

Efficacy proof-of-concept from a phase 1 study of a novel therapeutic peptide, ST101, targeting the oncogenic transcription factor C/EBPβ in patients with refractory solid tumors

2022 ST101 non-clin pkpd Final thuymb

April 11, 2022

Characterizing the PK/PD relationship of C/EBPβ antagonist peptide ST101 in a mouse orthotopic breast cancer model

ST316 Final thumb

April 11, 2022

β-catenin antagonist peptide, ST316, attenuates Wnt-dependent oncogenic activity

Sapience Therpeutics _ESMO 2021 poster thumb

September 16, 2021

Efficacy, safety, pharmacokinetic and pharmacodynamic data from phase 1 dose escalation of a novel therapeutic peptide, ST101, targeting the oncogenic transcription factor C/EBPβ, in patients with advanced and metastatic solid tumors

Sapience AACR poster 2021 - #964 thumb

April 9, 2021

β-catenin antagonist peptide attenuates Wnt-dependent oncogenic activity

Sapience AACR Poster 2021 - #959 thumb

April 9, 2021

C/EBPβ antagonist peptide, ST101, as a potential therapeutic approach in breast cancer

Sapience Therapeutics - 2020 AACR poster - beta-catenin thumb

June 22, 2020

β-catenin antagonist peptide attenuates oncogenic gene transactivation and promotes antitumor activity in breast cancer models

Sapience Therapeutics - 2020 AACR poster - ST101 thumb

June 22, 2020

C/EBPβ antagonist peptide, ST101, attenuates oncogenic gene transactivation in cancer cells to drive antitumor activity

Cell penetrating peptide, ST101, disrupts ATF5 regulation

April 1, 2019

Cell penetrating peptide, ST101, disrupts ATF5 regulation of anti-apoptotic Bcl-2 family proteins, resulting in induction of cancer cell death in vitro and tumor growth inhibition/regression in vivo

sapeince logo

 ©2025 Sapience Therapeutics, Inc.
All Rights Reserved

Explore

  • About
  • Approach
  • Pipeline
  • Clinical Trials
  • News & Events
  • Careers
  • Contact

Contact

520 White Plains Road
Second Floor
Tarrytown, NY 10591

Tel: (914) 418-5100

Follow Us

linkedin logo

Legal

  • Policies
  • Disclaimer
logo
  • About
    • Overview
    • Management
    • Directors
    • Advisors
  • Approach
    • Overview
    • Spears™
    • SPARCs™
    • Platforms
  • Pipeline
    • Overview
    • Lucicebtide (ST101)
    • ST316
    • FraAP Program
  • Clinical Trials
    • Overview
    • Lucicebtide (ST101)
    • ST316
    • Expanded Access
  • News & Events
    • Press Releases
    • Events
    • Publications
    • Presentations
    • Email Alerts
  • Careers
    • Careers
    • Open Opportunities
  • Contact